Roche has seen its pharmaceutical sales increase in 2019 as it fought off the impact of cheaper near-copies of its most successful drugs with a batch of new medicines.
Pfizer has announced the launch of its competitors to Roche’s ‘big three’ cancer drugs in the US, at a “substantially discounted price” compared with the originators.
The US regulator has approved Epizyme’s Tazverik (tazemetostat) for advanced sarcoma, providing a new option for a disease where there are high recurrence rates and toxicity issues with est
